H-C-572  
Cymbalta
European Public Assessment Report
Revision 11 - Published 18/01/10

Glossary

BG = bălgarski
ES = español
CS = čeština
DA = dansk
DE = Deutsch
ET = eesti keel
EL = elliniká
EN = English
FR = français
IT = italiano
LV = latviešu valoda
LT = lietuvių kalba
HU = magyar
MT = Malti
NL = Nederlands
PL = polski
PT = português
RO = română
SK = slovenčina
SL = slovenščina
FI = suomi
SV = svenska

 
BG ES CS DA DE ET EL EN FR IT LV LT HU MT NL PL PT RO SK SL FI SV   See Glossary of language codes...
u u u u u u u u u u u u u u u u u u u u u u   Summary for the public
spacer
u u u u u u u u u u u u u u u u u u u u u u   All Authorised Presentations
spacer
              u                               Scientific Discussion (6)
spacer
              u                               Procedural steps taken before authorisation
spacer
              u                               Procedural steps taken and scientific information after authorisation (8)
spacer
   
Product Information*  

20/11/2009 Cymbalta-H-C-572-II-36

  
BG ES CS DA DE ET EL EN FR IT LV LT HU MT NL PL PT RO SK SL FI SV   See Glossary of language codes...
spacer
u u u u u u u u u u u u u u u u u u u u u u  
spacer
   

(*)This document includes:

Annex I - Summary of product Characteristics
Annex IIA - Manufacturing Authorisation Holder responsible for Batch Release
Annex IIB - Conditions of the Marketing Authorisation
Annex IIIA - Labelling
Annex IIIB - Package Leaflet

Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
   
© 1995-2010 European Medicines Agency
Send all queries regarding the Web content and functionality to: info@ema.europa.eu		  

EPARs for authorised medicinal products for human use